Search Results

Your search for Kimberley T. Lee, MD, MHS, and Cesar A. Santa-Maria, MD, MSCI matches 2 pages

Showing 1 - 2

By Kimberley T. Lee, MD, MHS, and Cesar A. Santa-Maria, MD, MSCI / October 10, 2020 - Supplement: Breast Almanac

Neratinib in Previously TreatedHER2-Positive Metastatic Breast Cancer: Point of View From the NALA Trial

Neratinib is an oral pan-HER tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) for two indications. The first is as adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab therapy. The second is in combination with...

breast cancer

By Kimberley T. Lee, MD, MHS, and Cesar A. Santa-Maria, MD, MSCI / September 25, 2020

Neratinib in Previously Treated HER2-Positive Metastatic Breast Cancer: Point of View From the NALA Trial

Apr

Today In Oncology

Search Results

Your search for Kimberley T. Lee, MD, MHS, and Cesar A. Santa-Maria, MD, MSCI matches 2 pages

Neratinib in Previously TreatedHER2-Positive Metastatic Breast Cancer: Point of View From the NALA Trial

Neratinib in Previously Treated HER2-Positive Metastatic Breast Cancer: Point of View From the NALA Trial

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs

AI Model May Help Predict Treatment Responses Select Most Effective Cancer Therapies in Patients With Cancer

In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer

Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved

Potential Protective Effects of Aspirin Against Colorectal Cancer